Publications by authors named "A Calabuig"
Background: There is a large variability in the management of conduction disturbances (CDs) after transcatheter aortic valve replacement (TAVR).
Objective: This study aimed to validate a prespecified algorithm for managing CDs in patients undergoing TAVR.
Methods: This was a prospective multicenter study including consecutive patients without prior pacemaker undergoing TAVR.
Corrigendum to "Tankyrase1/2 inhibitor XAV-939 reverts EMT and suggests that PARylation partially regulates aerobic activities in human hepatocytes and HepG2 cells" [Biochem. Pharmacol. 227 (2024) 116445].
Biochem Pharmacol
November 2024
We analyzed the effect of respiratory swings on interpreting intravascular pulmonary vascular pressures (PVPs) in chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) candidates for lung transplantation (LTx) and the role of the alterations in pulmonary function tests on the dynamic respiratory variations. Twenty-eight consecutive patients were included. All patients underwent a complete hemodynamic study (right atrial, mean pulmonary arterial, and pulmonary arterial occlusion pressures [RAP, mPAP, and PAOP]-) and pulmonary function testing (force vital capacity [FVC], forced expiratory volume in the first second [FEV1], and residual volume [RV]).
View Article and Find Full Text PDFArticle Synopsis
- Percutaneous mitral paravalvular leak (PVL) closure is a safe and effective alternative to surgery, but its long-term outcomes are not well-studied. The study focused on how successful closure impacts long-term patient outcomes.* -
- Researchers analyzed data from 90 patients undergoing their first mitral PVL closure attempt between 2010 and 2021, finding that while 91.1% had a reduction in leak severity, only 52.2% achieved successful closure.* -
- After a median follow-up of 3.2 years, those with procedural failure faced significantly higher mortality rates, particularly from cardiovascular causes, indicating that successful PVL closure greatly benefits long-term health.*
Background: Data comparing valve systems in the valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) field have been obtained from retrospective studies.
Objectives: The authors sought to compare the 1-year hemodynamic performance and clinical outcomes between balloon-expandable valves (BEV) SAPIEN 3/ULTRA (Edwards Lifesciences) and self-expanding valves (SEV) Evolut R/PRO/PRO+ (Medtronic) in ViV-TAVR.
Methods: Patients with a failed small (≤23 mm) surgical valve undergoing ViV-TAVR were randomized to receive a SEV or a BEV.